Medium dose cyproterone acetate (CPA): Effects on hormone secretion and on spermatogenesis in men*
Literature (24)
- et al.
Continuous oral low-dosage cyproterone acctate for fertility requlation in the male ? — A trend analysis in 15 volunteers
Contracoption
(1976) - et al.
Effects of cyproterone acetate on reproductive functions in normal human males
Contraception
(1976) - et al.
Cyproterone acetate (CPA) — a potential male contraceptive: further studies on the interactions with endocrine parameters
J. Steroid Biochem.
(1978) - et al.
Steroid binding in polyacrylamide gels
J. Biol. Chem.
(1974) - et al.
Effect of cyproterone acetate on gonadal function in men
J. Steroid Biochem.
(1978) - et al.
Untersuchungen zum Wirkungsmechanismus der Antiandrogene Cyproteron und Cyproteronacetat beim Menschen (Gonadotropin-, Plasmatestosteron- und norphologische Keimdrüsenuntersuchungen) Verh
Dtsch. Ges. Inn. Med.
(1970) - et al.
Effects of cyproterone acotate (CPA) on pituitary gonadotropin release and on androgen secretion before and after LH-RH double stimulation tests in men
Intern. J. Androl. Suppl.
(1978) Empfehlungen zur Nomenklatur in der Andrologie
Andrologie
(1970)- et al.
Short term regulation of LH and FSH secretion in cyclic women. III. Effects of varying doses of two consecutive LH-RH injections on pituitary and ovarian response
Acta endocr. (Kbh.)
(1979) - et al.
The routine spermogram in the assessment of male fertility, I. Spermiograms “normal” by nine variables
Intern. J. Androl.
(1979)
The hormonal effects of antiandrogen (SH-714) treatment in man
Invest. Urol.
The influence of antiandrogens on the excretion of LH, FSH and 17-Ketosteroids in males
Horm. Metab. Res.
Cited by (25)
Differential Effects of Cyproterone Acetate vs Spironolactone on Serum High-Density Lipoprotein and Prolactin Concentrations in the Hormonal Treatment of Transgender Women
2016, Journal of Sexual MedicineCitation Excerpt :A recent study reported that although prolactin levels increased in transgender women on oral estradiol and CPA, levels returned to baseline after cessation of CPA after gonadectomy, suggesting that CPA, rather than estradiol, contributed to the increase in prolactin.18 There is evidence of prolactin increases with CPA in other settings, such as prostate cancer,22 breast cancer,23 and male contraception.24 The molecular mechanism by which this occurs has yet to be characterized, although there is some evidence from studies in primates associating CPA with lactotroph hypertrophy, hyperplasia, and an abundance of cytoplasmic RNA for prolactin.25
How should we understand the term androgen deprivation therapy?
2012, European UrologyUse of progestins in male contraception
2003, SteroidsMale hormonal contraception
2000, Best Practice and Research: Clinical Endocrinology and MetabolismMale contraception
1996, Bailliere's Clinical Obstetrics and Gynaecology
- *
This study was supported by a research grant from the WHO: Task Force Program on Regulation of Male Fertility (WHO TO 1472).